- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00102440
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout (FACT)
January 31, 2012 updated by: Takeda
A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout
The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a randomized, controlled, double-blind study of 52 weeks duration.
Subjects receiving prior urate-lowering therapy underwent a 2-week washout period prior to randomization.
Subjects were then randomized to one of three treatment groups: febuxostat 80 milligram (mg), febuxostat 120 mg, or allopurinol 300 mg.
Naproxen (250 mg twice daily) or colchicine (0.6 mg once daily) was provided for prophylaxis of acute gout flares during the washout period and the first 8 weeks of double-blind treatment.
Study Type
Interventional
Enrollment (Actual)
760
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meeting the preliminary criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout.
- Serum uric acid ≥ 8.0 milligrams per deciliter (mg/dL) at Baseline
Exclusion Criteria:
- Serum creatinine >1.5 mg/dL
- Calculated creatinine clearance of <50 milliliters per minutes (mL/min)
- Pregnancy or lactation;
- Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (>325 mg) or other salicylates;
- Body Mass Index (BMI) >50 kilogram per meter²(kg/m²);
- A history of xanthinuria, active liver disease, or hepatic dysfunction;
- A history of alcohol abuse or intake of 14 or more alcohol-containing drinks/week.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Febuxostat 80 mg QD
|
Febuxostat 80 mg, orally, once daily for up to 52 weeks.
Other Names:
Febuxostat 120 mg, orally, once daily for up to 52 weeks.
Other Names:
|
EXPERIMENTAL: Febuxostat 120 mg QD
|
Febuxostat 80 mg, orally, once daily for up to 52 weeks.
Other Names:
Febuxostat 120 mg, orally, once daily for up to 52 weeks.
Other Names:
|
ACTIVE_COMPARATOR: Allopurinol 300 mg QD
|
Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)
Time Frame: Last 3 Visits (up to 52 weeks)
|
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable.
A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used.
The last 3 visits used may have differed for each subject.
|
Last 3 Visits (up to 52 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit
Time Frame: Week 28
|
Serum urate values were obtained at the Week 28 visit.
The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized.
|
Week 28
|
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit
Time Frame: Week 52
|
Serum urate values were obtained at the Week 52 visit.
The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 52 visit was summarized.
|
Week 52
|
Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit
Time Frame: Final Visit (up to 52 weeks)
|
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized.
The final visit was the last visit at which a serum urate value was collected.
The timing of the final visit may have differed for each subject.
|
Final Visit (up to 52 weeks)
|
Percent Change From Baseline in Serum Urate Levels at Week 28.
Time Frame: Baseline and Week 28
|
Serum urate values were obtained at the Week 28 visit.
The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized.
|
Baseline and Week 28
|
Percent Change From Baseline in Serum Urate Levels at Week 52.
Time Frame: Baseline and Week 52
|
Serum urate values were obtained at the Week 52 visit.
The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized.
|
Baseline and Week 52
|
Percent Change From Baseline in Serum Urate Levels at Final Visit
Time Frame: Baseline and Final Visit (up to 52 weeks)
|
The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized.
The Final visit was the last visit with a serum urate value.
The timing of the final visit may have differed for each subject.
|
Baseline and Final Visit (up to 52 weeks)
|
Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
Time Frame: Baseline and Week 28
|
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit.
If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.
|
Baseline and Week 28
|
Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
Time Frame: Baseline and Week 52
|
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit.
If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.
|
Baseline and Week 52
|
Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
Time Frame: Baseline and Final Visit (up to 52 weeks)
|
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening.
If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.
|
Baseline and Final Visit (up to 52 weeks)
|
Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.
Time Frame: Baseline and Week 28
|
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit.
If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.
|
Baseline and Week 28
|
Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.
Time Frame: Baseline and Week 52
|
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit.
If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.
|
Baseline and Week 52
|
Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.
Time Frame: Baseline and Final Visit (up to 52 weeks)
|
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening.
If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.
|
Baseline and Final Visit (up to 52 weeks)
|
Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.
Time Frame: Weeks 8 through 52
|
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized.
A subject who reported more than 1 gout flare during this period was counted only once.
|
Weeks 8 through 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
- Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):585-91. doi: 10.1080/15257770802136032.
- Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.
- Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Primary Completion (ACTUAL)
February 1, 2004
Study Completion (ACTUAL)
February 1, 2004
Study Registration Dates
First Submitted
January 29, 2005
First Submitted That Met QC Criteria
January 28, 2005
First Posted (ESTIMATE)
January 31, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
February 2, 2012
Last Update Submitted That Met QC Criteria
January 31, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Metabolism, Inborn Errors
- Crystal Arthropathies
- Purine-Pyrimidine Metabolism, Inborn Errors
- Gout
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Gout Suppressants
- Allopurinol
- Febuxostat
Other Study ID Numbers
- C02-010
- U1111-1114-0184 (REGISTRY: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengActive, not recruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
Sheffield Hallam UniversityCherry Research CommitteeTerminated
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on Febuxostat
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
The Affiliated Hospital of Xuzhou Medical UniversityThe First People's Hospital of XuzhouUnknown
-
University of Mississippi Medical CenterTerminatedBlood Pressure | GoutUnited States
-
Benha UniversityNew Jeddah Clinic HospitalCompletedHemodialysis Complication | Hyperuricemia
-
Ningbo No. 1 HospitalNot yet recruitingNonalcoholic Fatty Liver DiseaseChina
-
AstraZenecaCompletedType 2 Diabetes | Albuminuria | HyperuricemiaUnited States
-
JW PharmaceuticalRecruitingGoutKorea, Republic of
-
TakedaCompleted